Latest Breaking News On - Lieber institute for brain development - Page 14 : comparemela.com
Capital Gazette shooter s sister testifies that her brother was obsessed with his court battle against the newspaper
washingtonpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from washingtonpost.com Daily Mail and Mail on Sunday newspapers.
Internships
kenyon.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kenyon.edu Daily Mail and Mail on Sunday newspapers.
Boehringer Ingelheim and The Lieber Institute for Brain Development to Collaborate to Develop Centrally Acting COMT Inhibitors for Treatment of Neuropsychiatric Disorders
businesswireindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswireindia.com Daily Mail and Mail on Sunday newspapers.
(1)
Through the partnership with the Lieber Institute, Boehringer Ingelheim obtains access to preclinical pipeline candidates of a potential first-in-class approach for the symptomatic treatment of neuropsychiatric disorders, including schizophrenia.
The new collaboration further expands Boehringer Ingelheim s circuitry-based approach to precision psychiatry and solidifies the company s commitment to provide better treatments for patients living with serious mental health conditions.
Boehringer Ingelheim and the Lieber Institute for Brain Development (LIBD) today announced a joint research and licensing collaboration focused on the development of novel centrally acting COMT (catechol-O-methyltransferase) inhibitors for the potential treatment of cognitive deficits in a spectrum of neuropsychiatric disorders, including schizophrenia. Aligning with a circuitry-based approach to precision psychiatry, the collaboration will leverage Boehringer Ingelheim s deep experience in central n
Listen 24 min MORE What schizophrenia feels like from an artist who suffers from paranoid schizophrenia. Art by Thomas Zapata (wikicommons)
Schizophrenia is a chronic neurological brain disorder that affects millions of people around the world. Although diagnosis and treatments have come a long way, it wasn’t until the last 20 to 30 years that scientists discovered certain genes that put people at risk for mental illness. How does this new science impact treatment, and why do mental disorders run in some families but not others? And how can our environment trigger these illnesses?
KCRW’s Jonathan Bastian talks about destigmatizing schizophrenia and how mapping the human genome has changed people’s understanding of mental illness. He’s joined by Daniel Weinberger, Johns Hopkins University psychology professor and director and CEO of the Lieber Institute for Brain Development.